3,9-dihydroxy-8-methoxy-dibenzo[b,d]pyran-6-one | 713519-19-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3,9-dihydroxy-8-methoxy-dibenzo[b,d]pyran-6-one
• 英文别名: 8-O-Methyl-urolithin C；3,9-dihydroxy-8-methoxybenzo[c]chromen-6-one
• CAS: 713519-19-8
• 化学式: C₁₄H₁₀O₅
• 分子量: 258.23
• InChiKey: VSSKAHKUAQIXLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,9-dihydroxy-8-methoxy-dibenzo[b,d]pyran-6-one 在 dimethyl sulfide borane 、 potassium carbonate 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 生成 3,9-Diisopropyloxy-8-methoxy-6H-dibenzo[b,d]pyran
  参考文献：
  名称：

  一些新的二苯并吡喃酮和二苯并吡喃的合成和生物学活性：寻找潜在的雌激素受体激动剂和拮抗剂。

  摘要：

  在继续寻找新的雌激素激动剂或拮抗剂并扩展对苯并吡喃相关化合物的探索方面，已经合成了在3,4-二芳基苯并二氢吡喃和2,3-二芳基苯并吡喃的活性分子之间架桥的一些新的三环分子。已经进行了在不同位置用已知的赋予激动剂或拮抗剂活性的元素进行结构修饰以制备所需的分子。筛选目标化合物的抗骨质疏松（激动剂）和抗子宫营养（拮抗剂）活性，发现它们具有中等活性。

  DOI：

  10.1016/j.bmc.2004.02.018
• 作为产物：
  描述：

  在 sodium hydroxide 、 乙酸酐 、 copper(II) sulfate 作用下， 以 水 为溶剂， 生成 3,9-dihydroxy-8-methoxy-dibenzo[b,d]pyran-6-one
  参考文献：
  名称：

  一些新的二苯并吡喃酮和二苯并吡喃的合成和生物学活性：寻找潜在的雌激素受体激动剂和拮抗剂。

  摘要：

  在继续寻找新的雌激素激动剂或拮抗剂并扩展对苯并吡喃相关化合物的探索方面，已经合成了在3,4-二芳基苯并二氢吡喃和2,3-二芳基苯并吡喃的活性分子之间架桥的一些新的三环分子。已经进行了在不同位置用已知的赋予激动剂或拮抗剂活性的元素进行结构修饰以制备所需的分子。筛选目标化合物的抗骨质疏松（激动剂）和抗子宫营养（拮抗剂）活性，发现它们具有中等活性。

  DOI：

  10.1016/j.bmc.2004.02.018

文献信息

• Exploration of Novel Urolithin C Derivatives as Non-Competitive Inhibitors of Liver Pyruvate Kinase
  作者：Umberto Maria Battisti、Leticia Monjas、Fady Akladios、Josipa Matic、Eric Andresen、Carolin H. Nagel、Malin Hagkvist、Liliana Håversen、Woonghee Kim、Mathias Uhlen、Jan Borén、Adil Mardinoğlu、Morten Grøtli

  DOI：10.3390/ph16050668

  日期：——

  The inhibition of liver pyruvate kinase could be beneficial to halt or reverse non-alcoholic fatty liver disease (NAFLD), a progressive accumulation of fat in the liver that can lead eventually to cirrhosis. Recently, urolithin C has been reported as a new scaffold for the development of allosteric inhibitors of liver pyruvate kinase (PKL). In this work, a comprehensive structure–activity analysis of urolithin C was carried out. More than 50 analogues were synthesized and tested regarding the chemical features responsible for the desired activity. These data could pave the way to the development of more potent and selective PKL allosteric inhibitors.

  肝脏丙酮酸激酶是一种脂肪在肝脏中逐渐积累并最终导致肝硬化的疾病，抑制肝脏丙酮酸激酶有助于阻止或逆转非酒精性脂肪肝。最近，有报道称尿石素 C 是开发肝丙酮酸激酶（PKL）异位抑制剂的新支架。本研究对尿石素 C 进行了全面的结构-活性分析。我们合成了 50 多种类似物，并测试了这些类似物所具有的化学特征。这些数据可为开发更强效、更具选择性的 PKL 异位抑制剂铺平道路。
• Identification of Urinary and Intestinal Bacterial Metabolites of Ellagitannin Geraniin in Rats
  作者：Hideyuki Ito、Ayumu Iguchi、Tsutomu Hatano

  DOI：10.1021/jf0726942

  日期：2008.1.1

  Hydrolyzable tannins, including ellagitannins, occur in foods such as berries and nuts. Various biological activities, including antioxidant, antiviral, and antitumor activities, have been noted and reported for ellagitannins, but the absorption and metabolism of purified ellagitannins are poorly understood. We describe herein the characterization of urinary and intestinal microbial metabolites in rats after the ingestion of ellagitannins. Urine samples were collected after oral administration of ellagitannins such as geraniin (1), corilagin (2), and their related polyphenols. The suspension of rat intestinal microflora. was anaerobically incubated with ellagitannins. Each sample was separated by column chromatography and/or preparative HPLC to give seven metabolites, M1-M7. The structures of these metabolites were determined on the basis of spectroscopic data and chemical evidence. These compounds, except for M1, were characterized as ellagitannin metabolites for the first time. Furthermore, among four major metabolites (M1-M4) in urine, M2 showed an antioxidant activity comparable to intact geraniin and related polyphenols.
• METHOD FOR PRODUCING UROLITHINS
  申请人：DAICEL CORPORATION

  公开号：US20190323045A1

  公开（公告）日：2019-10-24

  An object of the present invention is to provide a method for eliminating the hydroxyl group at the 9-position of a urolithin to produce another kind of urolithin. This object is achieved by a method for producing a second urolithin, including Step (a): allowing, in a solution containing a first urolithin, a microorganism having an ability to produce the second urolithin from the first urolithin to produce the second urolithin from the first urolithin.